ISSN 2220-315x (online)

World Journal of *Experimental Medicine*

Quarterly Volume 15 Number 4 December 20, 2025

Published by Baishideng Publishing Group Inc

World Journal of Experimental Medicine

Contents

Quarterly Volume 15 Number 4 December 20, 2025

REVIEW

Singla N, Mittal P, Babu MA, V Menon S, Ray S, Ali H, Purohit M, Goyal K, Mishra R, Hussain MS, Rekha A, Gupta G. Pinocembrin as a novel anti-cancer agent: Exploring preclinical evidence along with therapeutic potential. *World J Exp Med* 2025; 15(4): 110482 [DOI: 10.5493/wjem.v15.i4.110482]

Katchieva PK, Katchieva KK, Kipkeeva FI, Kharaeva ZF, Smeianov VV. Kefir revisited: Insights from the North Caucasus. *World J Exp Med* 2025; 15(4): 112191 [DOI: 10.5493/wjem.v15.i4.112191]

Al-Beltagi M. Clinical hypnosis in pediatric care: An adjunctive tool or therapeutic illusion. *World J Exp Med* 2025; 15(4): 114554 [DOI: 10.5493/wjem.v15.i4.114554]

MINIREVIEWS

Anirvan P, Giri S, Malakar S, Praharaj DL. Role of sodium-glucose cotransporter 2 inhibitors in liver diseases. *World J Exp Med* 2025; 15(4): 106403 [DOI: 10.5493/wjem.v15.i4.106403]

Rusman RD, Akil F, Parewangi ML, Daud NA, Bachtiar R, Kusuma SH, Rifai A. Gut microbiota and metabolic-associated steatosis liver disease: Unveiling mechanisms and opportunities for therapeutic intervention. *World J Exp Med* 2025; 15(4): 107316 [DOI: 10.5493/wjem.v15.i4.107316]

Mehta H, Gupta S, Hatwal J, Sohal A, Batta A, Mohan B. Psoriasis and atrial fibrillation: Exploring the intersection. *World J Exp Med* 2025; 15(4): 107425 [DOI: 10.5493/wjem.v15.i4.107425]

Burke A, Sanyaolu A, Ray A. Bacteria in neoplastic diseases: A brief note on Wilms tumor. *World J Exp Med* 2025; 15(4): 108221 [DOI: 10.5493/wjem.v15.i4.108221]

Bajpai J, Saxena M, Agarwal U, Pradhan A. Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea. *World J Exp Med* 2025; 15(4): 109762 [DOI: 10.5493/wjem.v15.i4.109762]

Aggarwal S, Choudhary V, Kothawala A, Mourad D, Agarwal C, Amin JV, Mylavarapu M, Chauhan S, Desai R. Pregnancy and diabetes: Emerging insights from contemporary diabetes research. *World J Exp Med* 2025; 15(4): 109839 [DOI: 10.5493/wjem.v15.i4.109839]

Meristoudis G, Savvidis C, Ilias I. Chronotherapeutic optimization of radioactive iodine therapy in differentiated thyroid cancer: The rationale for evening administration. *World J Exp Med* 2025; 15(4): 110893 [DOI: 10.5493/wjem.v15.i4.110893]

Ramos-Gregorio CO, Tremillo-Maldonado O, Silveira F, Schuch LF, Pereira-Prado V, Sicco E, Soto-Najera AC, GómezPalacio-Gastélum M, Isiordia-Espinoza M, Muñoz-Ibarra JJ, Toral-Rizo V, Bologna-Molina R. Multifocal epithelial hyperplasia: Clinical features, diagnosis and management challenges. *World J Exp Med* 2025; 15(4): 114368 [DOI: 10.5493/wjem.v15.i4.114368]

ORIGINAL ARTICLE

Observational Study

Akimova NS, Konshina LE, Runnova AE, Zhuravlev MO, Bogdanova TM, Kiselev AR, Shvarts YG. Short-term blood pressure variability as an indicator of the adaptive capacity of patients with chronic heart failure. *World J Exp Med* 2025; 15(4): 110904 [DOI: 10.5493/wjem.v15.i4.110904]

Von Ranke NL, Zhang W, Anokhin P, Hulscher N, McKernan K, Mccullough P, Catanzaro J. Synthetic messenger RNA vaccines and transcriptomic dysregulation: Evidence from new-onset adverse events and cancers post-vaccination. *World J Exp Med* 2025; 15(4): 113869 [DOI: 10.5493/wjem.v15.i4.113869]

Prospective Study

Sundaram KRM, Alwar TK, Nannapan R, Mohanakrishnan VV, Silambanan S. Association of inflammatory, genetic, and epigenetic markers with Kellgren-Lawrence grading in post-traumatic osteoarthritis of knee: A protocol. *World J Exp Med* 2025; 15(4): 107843 [DOI: 10.5493/wjem.v15.i4.107843]

Parija S, Chakraborty K, Sahu RN, Nayak B, Rathod RS. Ganglion cell complex and retinal nerve fiber layer thickness in predicting visual outcome in brain tumors after surgery. *World J Exp Med* 2025; 15(4): 108702 [DOI: 10.5493/wjem.v15.i4.108702]

Yadav B, Pilania J, Kant R, Omar BJ, Saini S, Panwar VK, Bahurupi Y, Panda PK. Stepwise model to differentiate pathogenic from non-pathogenic organisms in urinary isolates: Effectiveness, safety, and feasibility prospective study. *World J Exp Med* 2025; 15(4): 109134 [DOI: 10.5493/wjem.v15.i4.109134]

Senchukova MA, Zubareva EY, Saidler NV, Krivolapova LV. Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant. *World J Exp Med* 2025; 15(4): 110890 [DOI: 10.5493/wjem.v15.i4.110890]

Randomized Controlled Trial

Dhawan R, Mittal R, Kumar A, Laller KS, Gill PS, Rag A, Mittal N. Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial. *World J Exp Med* 2025; 15(4): 111542 [DOI: 10.5493/wjem.v15.i4.111542]

Basic Study

Joseph JHM, Babu Deva Irakkam MP, Kandasamy M. Proneurogenic and microglial modulatory properties of botulinum neurotoxin in the hippocampus of aging experimental mice. *World J Exp Med* 2025; 15(4): 108187 [DOI: 10.5493/wjem.v15.i4.108187]

Panchannavar GS, Angadi PV. Immunohistochemical expression of epithelial mesenchymal transition proteins ZEB1 and E-cadherin in oral leukoplakia and oral squamous cell carcinoma. *World J Exp Med* 2025; 15(4): 110372 [DOI: 10.5493/wjem.v15.i4.110372]

Abdelsalam HM, Abdelghany AM, Ahmed WA, Diab AA, Abdellateif MS. *Ferula assafoetida* induced colon cancer cells differentiation through JNK/MAPK signalling pathway activation. *World J Exp Med* 2025; 15(4): 110757 [DOI: 10.5493/wjem.v15.i4.110757]

Kumar KCP, Sahoo S, Adhya AK, Gaikwad MR, Ganapathy A, Ravi PK. Evaluating palmitoyl-protein thioesterase 1 in oral squamous cell carcinoma: A novel indicator of tumor behavior and therapeutic response. *World J Exp Med* 2025; 15(4): 110917 [DOI: 10.5493/wjem.v15.i4.110917]

SYSTEMATIC REVIEWS

Palabiyik AA. Efficacy of beta-blockers in the treatment of hematidrosis: A systematic review. *World J Exp Med* 2025; 15(4): 110936 [DOI: 10.5493/wjem.v15.i4.110936]

Kumari M, Kumar N, Meghwar R, Rai R, Rahul F, Hassan MA, Kumar K, Kumar H, Chaudhary MHN, Zahid K, Alam F, Jawed I, Kumar D, Jabeen S, Qadir U, Asim R. Molecular insights from skin biopsies: Deciphering microvascular pathology in peripheral vascular diseases. *World J Exp Med* 2025; 15(4): 111043 [DOI: 10.5493/wjem.v15.i4.111043]

CASE REPORT

Alkhadidi F, AlSharif H, AlQthami A, Alkhaldi SH, Alsuwat SA, Abosabie SA, Abosabie SA, Kamal NM. Novel homozygous *C3orf67* gene variant associated with primary ciliary dyskinesia in a Saudi pediatric patient: A case report. *World J Exp Med* 2025; 15(4): 108404 [DOI: 10.5493/wjem.v15.i4.108404]

ABOUT COVER

AIMS AND SCOPE

The primary aim of the *World Journal of Experimental Medicine* (*WJEM*, *World J Exp Med*) is to provide scholars and readers from various fields of experimental medicine with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJEM mainly publishes articles reporting research results and findings obtained in the field of experimental medicine and covering a wide range of topics including clinical laboratory medicine (applied and basic research in hematology, body fluid examination, cytomorphology, genetic diagnosis of hematological disorders, thrombosis and hemostasis, and blood typing and transfusion), biochemical examination (applied and basic research in laboratory automation and information system, biochemical methodology, and biochemical diagnostics), *etc.*

INDEXING/ABSTRACTING

The *WJEM* is now abstracted and indexed in PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The *WJEM*'s CiteScore for 2024 is 1.7 and Scopus CiteScore rank 2024: Internal medicine is 109/171.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Cai-Hong Wang*; **Production Department Director:** *Xiao-Mei Zheng*; **Cover Editor:** *Ji-Hong Liu.*

NAME OF JOURNAL
World Journal of Experimental Medicine

ISSN
ISSN 2220-315x (online)

LAUNCH DATE
December 20, 2011

FREQUENCY
Quarterly

EDITORS-IN-CHIEF
Jian Wu

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF
Fang Gong

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2220-315x/editorialboard.htm

PUBLICATION DATE
December 20, 2025

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

POLICY OF CO-AUTHORS
https://www.wjgnet.com/bpg/GerInfo/310

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

World Journal of Experimental Medicine

Submit a Manuscript: https://www.f6publishing.com

World J Exp Med 2025 December 20; 15(4): 113869

DOI: 10.5493/wjem.v15.i4.113869

ISSN 2220-315x (online)

ORIGINAL ARTICLE

Observational Study

Synthetic messenger RNA vaccines and transcriptomic dysregulation: Evidence from new-onset adverse events and cancers post-vaccination

Natalia Lidmar Von Ranke, Wei Zhang, Philipp Anokhin, Nicolas Hulscher, Kevin McKernan, Peter Mccullough, John Catanzaro

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade C
Novelty: Grade D
Creativity or Innovation: Grade D
Scientific Significance: Grade D

P-Reviewer: D'Agostino S, PhD, Postdoc, Italy

Received: September 5, 2025
Revised: October 1, 2025
Accepted: October 24, 2025
Published online: December 20, 2025
Processing time: 105 Days and 14.4 Hours

Natalia Lidmar Von Ranke, Wei Zhang, Philipp Anokhin, John Catanzaro, Development of R and D, Neo7Bioscience, Dallas, TX 75032, United States

Nicolas Hulscher, Department of Epidemiology, McCullough Foundation, Dallas, TX 75032, United States

Kevin McKernan, Development of R and D, Medicinal Genomics, Beverly, MA 01915, United States

Peter Mccullough, Development of R and D, McCullough Foundation, Dallas, TX 75032, United States

Corresponding author: John Catanzaro, MD, PhD, Development of R and D, Neo7Bioscience, 2500 Summer Lee Dr, Rockwall, Dallas, TX 75032, United States.
john.catanzaro@neo7bioscience.com

Abstract

BACKGROUND

Synthetic messenger RNA (mRNA) vaccines have raised concerns regarding prolonged spike protein expression, immune activation, and potential off-target effects.

AIM

To investigate transcriptomic alterations in individuals with new-onset adverse events or cancer following mRNA coronavirus disease 2019 vaccination.

METHODS

Bulk RNA sequencing was performed on peripheral blood from two patient groups: (1) Individuals with new-onset nonmalignant adverse events; and (2) Individuals newly diagnosed with cancer post-vaccination. A control group of normal individuals was used for comparison. Differential gene expression was analyzed using DESeq2, and Gene Set Enrichment Analysis was conducted using the MSigDB database and custom gene sets.

RESULTS
Both vaccine patient groups displayed widespread transcriptional dysregulation. In the nonmalignant adverse event group, hallmark enrichments included mitochondrial dysfunction, proteasome-mediated stress, transcriptomic instability, and systemic inflammation. The cancer group exhibited additional hallmarks of genomic instability and epigenetic reprogramming. Nonsense-mediated decay, ribosomal stress, and myelocytomatosis oncogene activation were prominent in both groups, while immune signaling *via* toll-like receptors and type I interferons was particularly elevated in cancer patients. The observed transcriptomic profiles indicate cellular stress responses, mitochondrial dysfunction, and immune dysregulation following exposure to mRNA vaccines, potentially in susceptible individuals.

CONCLUSION
Shared and distinct molecular signatures in both cohorts demonstrate underlying mechanisms contributing to post-vaccine symptomatology and complications, including oncogenesis and or progression of malignant disease. These findings underscore the need for a deeper investigation into the long-term safety of mRNA vaccines and host response variability.

Key Words: Coronavirus disease; Vaccine; RNA-seq; Immune dysregulation; Cancer

Core Tip: This study demonstrates that individuals experiencing new-onset adverse events or cancer after messenger RNA (mRNA) coronavirus disease 2019 vaccination exhibit widespread transcriptomic dysregulation. Bulk RNA sequencing revealed hallmarks of mitochondrial dysfunction, systemic inflammation, proteasome and ribosomal stress, and nonsense-mediated decay, with additional genomic instability and epigenetic reprogramming in cancer patients. Notably, myelocytomatosis oncogene activation and heightened immune signaling *via* toll-like receptors and type I interferons were observed. These findings highlight shared and distinct molecular signatures, underscoring the need for further investigation into long-term mRNA vaccine safety and host variability.

Citation: Von Ranke NL, Zhang W, Anokhin P, Hulscher N, McKernan K, Mccullough P, Catanzaro J. Synthetic messenger RNA vaccines and transcriptomic dysregulation: Evidence from new-onset adverse events and cancers post-vaccination. *World J Exp Med* 2025; 15(4): 113869
URL: https://www.wjgnet.com/2220-315x/full/v15/i4/113869.htm
DOI: https://dx.doi.org/10.5493/wjem.v15.i4.113869

INTRODUCTION

Synthetic messenger RNA (mRNA) vaccines represent a novel immunization platform that delivers chemically modified mRNA, encapsulated in lipid nanoparticles (LNPs), to encode and express viral antigens in human cells. The accelerated development of mRNA vaccines was primarily driven by the urgency of the coronavirus disease 2019 (COVID-19) pandemic, supported by emergency authorizations, platform-based manufacturing, and the parallel rather than sequential conduct of clinical trial phases. While initially promoted for their rapid production and strong immunogenicity, a growing body of evidence has identified a range of adverse events, including myocarditis, thrombosis, cerebrovascular accidents, amyloidogenesis, arthralgia, menstrual disorders, reproductive concerns, and new-onset malignancies[1-5]. These events have prompted renewed scrutiny of the molecular mechanisms triggered by synthetic mRNA constructs and their intracellular fate[6,7].

Unlike endogenous mRNA, vaccine-derived transcripts incorporate non-natural features such as N1-methyl-pseudouridine (m1Ψ) substitution, extended poly(A) tails, and optimized untranslated regions to enhance stability and translational efficiency. These same modifications may alter RNA metabolism and surveillance, contributing to ribosomal infidelity, +1 frameshifting, and defective protein folding[8,9]. Independent studies have reported reverse transcription of vaccine mRNA into DNA *via* endogenous long interspersed nuclear element-1 (LINE-1) elements, highlighting issues over genomic integration and persistent expression[8,10]. Recent analyses of BNT162b2 vaccine vials revealed residual plasmid DNA, including SV40 enhancer and antibiotic resistance genes, raising concerns over potential oncogenic risk from unintended genomic exposure[11-15]. Moreover, recent research has shown that spike protein translated from mRNA vaccines can persist in the circulation for extended periods, far beyond initial pharmacokinetic expectations, potentially sustaining inflammatory signaling and immune activation[16-18]. Finally, some studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bears molecular signatures consistent with synthetic genome assembly, raising further concerns about engineered RNA platforms and their potential unforeseen biological consequences[19]. These features collectively raise concerns regarding unintended cellular consequences of synthetic mRNA exposure.

To address this gap, we conducted a comparative transcriptomic analysis using bulk RNA-sequencing data from whole blood of patients with new-onset adverse events (group 1) and patients with new-onset cancers (group 2) following COVID-19 mRNA vaccination, alongside normal controls. Differential expression analysis and Gene Set Enrichment Analysis (GSEA) were performed to identify hallmark-specific molecular pathways perturbed in each group. By comparing these two profiles, this study aims to highlight potential transcriptomic disturbances associated with vaccine-related pathology and explore whether distinct or shared molecular hallmarks may underlie different post-vaccination clinical trajectories.

MATERIALS AND METHODS

Patient population characteristics and sample collection

We enrolled adult participants (≥ 18 years) who developed new-onset symptoms following administration of mRNA-based COVID-19 vaccines [BNT162b2 (pfizer) or mRNA-1273 (moderna)]. All participants provided written informed consent prior to inclusion.

The study population was divided into two groups: (1) Group 1: Consisting of three individuals who experienced post-vaccination non-malignant adverse events with symptoms emerging within one month of vaccination; and (2) Group 2: Comprising seven individuals diagnosed with new-onset malignancies within one year of vaccination. None of the participants in either group had a prior history of chronic disease or known genetic predisposition before vaccination and symptom onset. The clinical manifestations of each patient are summarized in Table 1. As a reference, RNA-seq data from 803 unvaccinated individuals were retrieved from the GTEx dataset[20]. These control samples were collected prior to the development of COVID-19 vaccines, ensuring that all control individuals were unvaccinated[21].

Peripheral blood samples were collected by licensed nurses at Neo7Bioscience-affiliated clinical sites, following institutional biosafety protocols. Venipuncture was performed using standard sterile technique, and whole blood was drawn into pre-labelled streck tubes and stored at 4 °C. Samples from group 1 (post-vaccination symptom group) were transported the same day in cooled containers to the Genomics Center at the University of North Texas for processing. Samples from group 2 (post-vaccination malignancy group) were collected into PAXgene Blood RNA Tubes (Qiagen) and transported at controlled temperature to Psomagen-Multiomics services and data analysis for downstream processing.

RNA extraction

Total RNA was extracted from whole blood using column-based purification workflows compatible with downstream RNA-seq. For group 1, RNA was extracted with the Quick-DNA/RNA Viral Kit (Zymo Research), including on-column DNase treatment to remove genomic DNA contamination. For group 2, RNA was extracted from the entire blood volume of a single PAXgene Blood RNA Tube using the PAXgene Blood RNA Kit (Qiagen), following the manufacturer's protocol. Extracted RNA was quantified and stored at -20 °C until further use. For both groups, RNA quality was assessed by electrophoretic profiling (Agilent TapeStation 4200 or equivalent), and only samples meeting quality thresholds (*e.g.*, RNA integrity number ≥ 7.0 or equivalent QC metrics) were advanced to library preparation.

Library preparation and complementary DNA synthesis and high-throughput sequencing

RNA-seq libraries were generated using strand-specific protocols with ribosomal RNA (rRNA) depletion to maximize detection of coding transcripts. For group 1, libraries were prepared using the Illumina TruSeq Stranded Total RNA Kit with Ribo-Zero depletion chemistry (Illumina). RNA was enzymatically fragmented, reverse-transcribed to complementary DNA (cDNA), end-repaired, A-tailed, adapter-ligated, and polymerase chain reaction (PCR)-amplified. Libraries were quantified fluorometrically, fragment sizes were verified by electrophoresis, and sequencing was performed on an Illumina NextSeq 550 (High Output v2.5, 300 cycles) with paired-end 150 bp reads.

For group 2, libraries were prepared using the Illumina Stranded Total RNA Ribo-Zero Plus Kit (Illumina), incorporating rRNA depletion and strand-specific cDNA synthesis. RNA was enzymatically fragmented, reverse-transcribed to first-strand cDNA, converted to double-stranded cDNA, end-repaired, adenylated, ligated to Illumina-specific adapters, and PCR-amplified. Library quality and fragment size distribution were assessed using D5000 ScreenTape on the Agilent TapeStation 4200. Libraries were stored at -20 °C before sequencing. Normalized and pooled libraries were sequenced on the Illumina NovaSeq X platform (NovaSeq X Series 25B Reagent Kit, 300 cycles), generating 151 bp paired-end reads to a target yield of 3.02 Gb per sample (approximately 20 million reads). PhiX was added at 1% as an internal control, and sequencing quality metrics (Q30 scores, %PF) were monitored in real time using Illumina's Sequencing Analysis Viewer.

Data preprocessing, quality control, and alignment

The raw sequencing data, in the form of paired-end fastq files, were first organized by sample and read type (R1 and R2). These fastq files were stored in a dedicated directory, and the cat command was used to group them based on their sample identifiers. The R1 and R2 files for each sample were then merged into a single file for each read type, resulting in forward and reverse merged files that were ready for downstream analysis.

Quality control checks were performed before the alignment step to ensure the integrity of the data. The sequencing reads were aligned to the human reference genome (hg38) using STAR[22], a widely used aligner for RNA sequencing data. STAR efficiently handles read alignment in a multi-threaded environment, optimizing processing time. The aligned reads were then outputted as BAM files, sorted by coordinate, which is standard practice for subsequent analysis steps.

Table 1 Summary of study participants, clinical manifestations, and diagnostic groupings

Patient ID	Group	Condition/symptoms
P1	1: Non-malignant adverse events	Brain fog and chronic fatigue
P2	1: Non-malignant adverse events	Cardiovascular injury, thrombosis, and chronic fatigue
P3	1: Non-malignant adverse events	Cardiovascular injury, thrombosis, and chronic fatigue
P4	2: Cancer	Glioblastoma multiforme
P5	2: Cancer	Prostate adenocarcinoma
P6	2: Cancer	Bladder tumor
P7	2: Cancer	Follicular lymphoma
P8	2: Cancer	Prostate cancer
P9	2: Cancer	Glioblastoma multiforme
P10	2: Cancer	Follicular lymphoma

Differential expression analysis and volcano plot visualization

To investigate transcriptomic alterations associated with mRNA vaccine–related outcomes, we performed two distinct differential expression analyses, each comparing one patient group to a common pool of normal controls (n = 803)[20]. The first comparison included individuals from group 1, who developed nonmalignant new-onset symptoms following mRNA vaccination (n = 3), while the second comprised individuals from group 2, diagnosed with cancer as a new-onset condition shortly after vaccination (n = 7). For both analyses, raw gene counts generated from Salmon[23] were input into DESeq2[24], which applied internal normalization and modeled dispersion using the negative binomial distribution. Shrinkage of $\log_2$ fold changes was performed using the "apeglm" method to improve effect size estimation, particularly for genes with low read counts.

To visualize the global patterns of gene expression, volcano plots were generated for each comparison. In these plots, the X-axis represents the $\log_2$ fold change, and the Y-axis represents the negative $\log_{10}$ of the adjusted P value. Genes with $\log_2$ fold change greater than +1 and an adjusted P value (P_{adj}) below 0.05 were considered significantly upregulated and were colored red, while those with $\log_2$ fold change less than -1 and $P_{adj} < 0.05$ were considered significantly downregulated and were colored blue. All remaining genes that did not meet these criteria were displayed in gray.

GSEA

To investigate transcriptomic disruptions associated with mRNA vaccine exposure, we analyzed RNA-seq data from two case groups: (1) Group 1: Comprising three individuals who developed new-onset vaccine-related adverse effects; and (2) Group 2: Consisting of seven individuals diagnosed with new-onset cancer following mRNA COVID-19 vaccination. Both groups were compared to a shared reference cohort of 803 individuals in a normal control group, whose RNA-seq data were retrieved from the GTEx dataset[20]. Differential gene expression analysis was conducted using DESeq2[24], and genes were ranked by $\log_2$ fold change to generate the input file for enrichment analysis.

We then performed GSEA using the preranked mode of the Broad Institute's GSEA 4.4.0 tool[25]. This approach was selected due to the significant class imbalance (3 samples *vs* 803 samples), as it improves the stability and interpretability of enrichment results. The "weighted" enrichment statistic was applied to incorporate both gene ranking and expression magnitude, enhancing sensitivity to biologically relevant perturbations. We used 1000 gene set permutations to estimate statistical significance and selected the "no collapse" option to retain gene symbols without alias mapping.

GSEA was systematically conducted across multiple MSigDB[26] collections: (1) H (Hallmark); (2) C2 (Kyoto Encyclopedia of Genes and Genomes and REACTOME); (3) C5 (Gene Ontology Biological Processes); (4) C7 (immunologic signatures); and (5) Custom gene sets including Gavish and curated grape seed extract-derived expression signatures. Enrichment results were interpreted based on the Normalized Enrichment Score (NES) and false discovery rate (FDR) (q value), selecting gene sets that were strongly enriched (positive NES) or suppressed (negative NES), which indicated upregulated or downregulated biological functions, respectively. For downstream analysis, only gene sets with FDR < 0.25 and absolute NES ≥ 1.5 were retained. The top enriched and suppressed gene sets were manually grouped into higher-order molecular pathway categories related to the patient's group symptoms.

To improve biological relevance, we excluded gene sets associated with non-blood tissues (*e.g.*, brain, retina, skin) and embryonic development, as these are unlikely to reflect transcriptional activity in peripheral blood. This filtering minimized noise and focused the analysis on pathways relevant to immune, inflammatory, and systemic responses.

Protein-protein interaction map

For constructing protein-protein interaction (PPI) networks, interaction information of differentially expressed genes from the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database was loaded onto the Cytoscape software platform[27,28]. The STRING database is a comprehensive online resource that compiles and predicts PPIs across numerous organisms[29,30]. It integrates known and predicted associations derived from experimental data, computational prediction methods, co-expression analyses, text mining, and curated databases. Each interaction is scored

and visualized in an interactive network, helping researchers explore functional associations between proteins within cellular pathways or biological processes[31]. The network can be viewed within STRING or can be exported directly to Cytoscape. Cytoscape combines biomolecular interaction networks with high-throughput expression data and other molecular states into an integrated conceptual network model.

RESULTS

To characterize the global transcriptional impact of mRNA vaccination in individuals with post-vaccination adverse outcomes, we conducted differential gene expression analyses comparing each patient group to the normal control cohort. As shown in Figure 1, the volcano plots visualize the distribution of gene expression changes for both group 1, new-onset nonmalignant post-vaccination symptoms (Figure 1A), and group 2, new-onset cancer diagnoses (Figure 1B). In both groups, a clear transcriptomic shift is observed, with hundreds of genes showing significant dysregulation. Notably, the cancer group exhibits a broader distribution of downregulated genes, including several with extreme fold change magnitudes, suggesting a profound suppression of key regulatory pathways.

GSEA was performed separately for both study groups: (1) Group 1: Comprising individuals with new-onset adverse events following mRNA COVID-19 vaccination; and (2) Group 2: Comprising individuals diagnosed with new-onset cancer after vaccination, to characterize transcriptomic disruptions associated with vaccine exposure. GSEA was conducted using the predefined *MSigDB* gene set collections, and the enriched gene sets were systematically grouped according to their relevance to higher-order molecular hallmark pathways (Tables 2 and 3). This pathway-based grouping enabled integrative interpretation of transcriptomic alterations across systems biology domains.

In group 1, the top enriched gene sets clustered into six key hallmark categories: (1) Mitochondrial electron transport dysfunction and reactive oxygen species (ROS); (2) Proteasome-mediated protein degradation stress; (3) Transcriptomic instability and translational stress; (4) Systemic inflammatory and immune response; (5) Endothelium dysfunction; and (6) Proliferative signaling and suppressed tumor control. In contrast, group 2 exhibited a distinct but overlapping enrichment pattern. The hallmarks identified in this group include: (1) Transcriptomic instability and translational stress; (2) Systemic inflammatory and immune response; (3) Endothelium dysfunction; (4) Proliferative signaling and suppressed tumor control; and (5) Genomic instability and epigenetic shift. As shown in Table 1, multiple gene sets within each hallmark category demonstrated strong enrichment scores (NES > 1.5 or < -1.5) and statistically significant FDR q values (FDR < 0.25), supporting the presence of coordinated molecular dysregulation. Representative enrichment score curves are provided in Supplementary Figures 1 and 2 to illustrate the distribution of gene ranks contributing to each hallmark. In addition, Supplementary Tables 1 and 2 provide the systematic names, standard names, and external links or source publications for all enriched gene sets.

To further explore the molecular landscape associated with vaccine-induced transcriptomic disruptions, PPI network analysis was conducted for the most significantly dysregulated genes in each study group. As shown in Figure 2, the PPI map for group 1 (individuals with new-onset adverse events post-vaccination) and Figure 3 shows the PPI map for group 2 (individuals with new-onset cancer following vaccination)

DISCUSSION

The rapid global rollout of RNA-based COVID-19 vaccines introduced a novel therapeutic platform involving synthetic mRNA and LNP delivery systems. While initially deployed to mitigate the spread of SARS-CoV-2, the long-term biological effects were unknown. Unlike conventional vaccines, these formulations induce host cells to express a viral spike glycoprotein from exogenous mRNA templates, raising concerns about unintended cellular responses[32]. Emerging clinical reports of persistent symptoms following vaccination – including neurological, cardiovascular, and immunological disturbances – have prompted scientific scrutiny into the molecular mechanisms potentially triggered by prolonged exposure to synthetic mRNA, its translation products, and associated immune activation[2,3,33,34]. To investigate these concerns, we performed GSEA on transcriptomic data from two distinct patient cohorts: (1) Individuals with new-onset post-vaccination adverse effects (group 1); and (2) Patients who developed cancer following mRNA vaccination (group 2). A summary of the transcriptomic alterations observed in each group is illustrated in Figure 4.

In the group 1 cohort, enrichment of gene sets related to mitochondrial electron transport indicates transcriptional disruption in core components of oxidative phosphorylation, particularly at complex I. The presence of variant-related enrichments involving PTEN-induced putative kinase 1, amyloid-beta, and alpha-synuclein suggests convergence associated with impaired mitophagy, neurodegeneration, and defective electron flow. These findings suggest that spike-mediated inflammation disrupts mitochondrial homeostasis. Indeed, previous studies indicate that the spike protein alters mitochondrial fusion-fission dynamics, suppressing the biogenesis of its regulators (nuclear respiratory factor 1/2, peroxisome proliferator-activated receptor gamma coactivator 1-alpha, mitochondrial transcription factor A), and increasing mitochondrial damage[35]. In addition, numerous studies have independently reported persistent mitochondrial dysfunction as a hallmark of long COVID[36-38], further supporting a mechanistic link between spike protein exposure and bioenergetic imbalance. Mitochondrial electron transport and ROS-related shifts are depicted in the PPI network (Figure 2D), highlighting key interconnected hub genes.

In the group 1 cohort, enrichment of proteasome-associated gene sets indicated activation of components of the ubiquitin-proteasome system. Upregulated proteins such as ubiquitin-40S ribosomal protein S27a (RPS27A), 26S proteasome subunit SEM1, polyubiquitin-B (UBB), and ubiquitin-60S ribosomal protein L40 (UBA52), along with several

Table 2 Gene set enrichment results for group 1 categorized by molecular pathway

Molecular pathways	MSigDB standard name	Normalized Enrichment Score	False discovery rate
Mitochondrial electron transport dysfunction and reactive oxygen species	KEGG_MEDICUS_REFERENCE_MITOCHONDRIAL_COMPLEX_UCP1_IN_THERMOGENESIS	1.86	0.11
	KEGG_MEDICUS_REFERENCE_ELECTRON_TRANSFER_IN_COMPLEX_I	1.70	0.10
	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_PINK1_TO_ELECTRON_TRANSFER_IN_COMPLEX_I	1.73	0.09
	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_ELECTRON_TRANSFER_IN_COMPLEX_I	1.69	0.09
	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SNCA_TO_ELECTRON_TRANSFER_IN_COMPLEX_I	1.66	0.11
	HALLMARK_OXIDATIVE_PHOSPHORYLATION	1.43	> 0.001
Proteasome-mediated protein degradation stress	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	1.78	0.12
	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_VCP_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	1.74	0.13
	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_SOD1_TO_26S_PROTEASOME_MEDIATED_PROTEIN_DEGRADATION	1.73	0.09
	GOBP_PROTEIN_CONTAINING_COMPLEX_REMODELING	-2.11	> 0.001
Transcriptomic instability and translational stress	REACTOME_EUKARYOTIC_TRANSLATION_INITIATION	3.11	> 0.001
	REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE	3.08	> 0.001
	REACTOME_NONSENSE_MEDIATED_DECAY_NMD	2.9	> 0.001
	KEGG_MEDICUS_REFERENCE_TRANSLATION_INITIATION	3.0	> 0.001
	GOBP_CYTOPLASMIC_TRANSLATION	2.60	> 0.001
	GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS	2.35	> 0.001
	GOBP_RIBOSOMAL_LARGE_SUBUNIT_BIOGENESIS	2.34	> 0.001
Systemic inflammatory and immune response	GSE22886_NAIVE_TCELL_VS_DC_UP	2.43	> 0.001
	GSE2405_0H_VS_9H_A_PHAGOCYTOPHILUM_STIM_NEUTROPHILS_UP	2.36	> 0.001
	GSE7400_CTRL_VS_CSF3_IN_VIVO_TREATED_PBMC_UP	2.27	> 0.001
	GSE7400_CTRL_VS_CSF3_IN_VIVO_TREATED_PBMC_DN	-1.93	> 0.001
	GSE6269_E_COLI_VS_STREP_PNEUMO_INF_PBMC_DN	-1.9	> 0.001

	GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE	-1.95	> 0.001
	GOBP_HUMORAL_IMMUNE_RESPONSE	-1.91	0.006
Endothelium dysfunction	HALLMARK_ANGIOGENESIS	-1.94	> 0.001
Proliferative signaling and suppressed tumor control	HALLMARK_MYC_TARGETS_V1	1.64	> 0.001
	GAVISH_3CA_MALIGNANT_METAPROGRAM_3_CELL_CYLCE_HMG_RICH	1.77	0.005
	HALLMARK_KRAS_SIGNALING_DN	-1.68	> 0.001
	HALLMARK_P53_PATHWAY	-1.50	0.038
	KEGG_MEDICUS_REFERENCE_WNT_SIGNALING_MODULATION_WNT_INHIBITOR	-1.56	0.89

The Table 2 displays the top gene sets within each category, along with their corresponding MSigDB identifiers, Normalized Enrichment Score (NES), and false discovery rate (FDR) q value. Positive NES values indicate upregulation, while negative NES values indicate downregulation of the gene sets in vaccinated samples (group 1) relative to controls. Gene sets were selected based on biological relevance and NES > |15| with FDR $q < 0.25$. Group 1 includes patients with new-onset adverse events following messenger RNA coronavirus disease 2019 vaccination ($n = 3$), compared with normal controls ($n = 803$ unvaccinated individuals from the GTEx dataset).



Figure 1 Transcriptome-wide differential expression profiles in vaccine-affected individuals. A: Volcano plot showing differential gene expression in individuals with new-onset adverse events following messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination ($n = 3$) compared to normal controls ($n = 803$); B: Volcano plot showing differential gene expression in individuals diagnosed with new-onset cancer shortly after receiving mRNA COVID-19 vaccination ($n = 7$) compared to the same control cohort. Each point represents a single gene plotted by $\log_2$ fold change (X-axis) and $-\log_{10}$ adjusted P value (P_{adj}) (Y-axis). Genes with significant upregulation ($\log_2FC > 1$, $P_{adj} < 0.05$) are marked in red, while significantly downregulated genes ($\log_2FC < -1$, $P_{adj} < 0.05$) are shown in blue. Non-significant genes appear in gray. These plots reveal widespread transcriptional dysregulation in both patient groups, serving as the foundation for subsequent pathway enrichment analysis.

core subunits of the 20S and 19S proteasome complexes, including PSMA2-5, PSMA8, PSMC1, and PSMD7 reflect increased transcriptional demand for protein degradation machinery, likely in compensation for misfolded or aggregated proteins. The enrichment of variant-associated gene sets linked to valosin-containing protein and super oxide dismutase 1 dysfunction further supports convergence with proteostasis disruption, a phenomenon commonly observed in neurodegenerative and proteinopathy-associated conditions. One potential driver of this sustained proteasomal activation is the prolonged presence of synthetic mRNA in circulation, which has been shown to persist beyond initial translation and may continuously stimulate the production of spike protein or aberrant translation products[16-18]. Moreover, persistence of vaccine-derived RNA has been demonstrated in human samples, including placental tissue up to 10 days post-vaccination[39] and plasma up to 28 days[40,41]. Identified persistence of vaccine-derived RNA in human heart tissue up to 30 days post-vaccination[42], demonstrated retention within lymph nodes for as long as 60 days, and Ota *et al* [43] recently reported mRNA detection in cerebral arteries 17 months post-vaccination[44]. Collectively, these findings underscore that synthetic mRNA and its byproducts may linger in diverse tissues for prolonged periods, continually engaging proteostatic and immune surveillance pathways. Additionally, emerging evidence suggests that the SARS-CoV-2 spike protein contains prion-like domains that are prone to misfolding and aggregation. These properties may be amplified in vaccine-induced expression, leading to persistent proteotoxic stress and neurodegenerative-like transcriptional profiles[8].

Transcriptomic Instability and Translational Stress was a dominant hallmark in both patient groups. mRNA stabilization, translation initiation, and protein synthesis rates are distinct yet interconnected regulatory nodes. The mRNA stabilization controls the substrate's half-life, determining the window of opportunity for translation. In contrast, translation initiation, often the rate-limiting step, involves the assembly of the ribosome and initiation factors (*e.g.*, eukaryotic initiation factor 4F) at the 5' cap and is highly responsive to cellular signaling and stress. These processes can

Table 3 Gene set enrichment results for group 2 categorized by molecular pathway

Molecular pathways	MSigDB standard name	Normalized Enrichment Score	False discovery rate
Transcriptomic instability and translational stress	REACTOME_SIRT1_NEGATIVELY_REGULATES_RRNA_EXPRESSION	3.08	> 0.001
	REACTOME_RNA_POLYMERASE_I_PROMOTER_ESCAPE	2.61	> 0.001
	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_SMALL_RNAS	2.63	> 0.001
	REACTOME_B_WICH_COMPLEX_POSITIVELY_REGULATES_RRNA_EXPRESSION	2.60	> 0.001
	REACTOME_POSITIVE_EPIGENETIC_REGULATION_OF_RRNA_EXPRESSION	2.54	> 0.001
	REACTOME_RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL	2.03	0.027
Systemic inflammatory and immune response	KEGG_MEDICUS_REFERENCE_TYPE_I_INTERFERON_TO_JAK_STAT_SIGNALING_PATHWAY	2.64	> 0.001
	KEGG_MEDICUS_PATHOGEN_HIV_TAT_TO_TLR2_4_NFKB_SIGNALING_PATHWAY	2.73	> 0.001
	KEGG_MEDICUS_REFERENCE_TYPE_I_IFN_SIGNALING_PATHWAY	2.64	> 0.001
	KEGG_MEDICUS_REFERENCE_RIG_I_NFKB_SIGNALING_PATHWAY	2.54	> 0.001
	KEGG_MEDICUS_REFERENCE_TLR3_IRF7_SIGNALING_PATHWAY	2.46	> 0.001
	KEGG_MEDICUS_REFERENCE_TLR7_8_9_IRF5_SIGNALING_PATHWAY	2.29	> 0.001
	KEGG_MEDICUS_REFERENCE_TLR7_9_IRF7_SIGNALING_PATHWAY	2.27	> 0.001
	KEGG_MEDICUS_REFERENCE_MDA5_IRF7_3_SIGNALING_PATHWAY	2.0	0.006
	KEGG_MEDICUS_REFERENCE_IFN_RIPK1_3_SIGNALING_PATHWAY	2.0	0.006
	KEGG_MEDICUS_REFERENCE_RIG_I_IRF7_3_SIGNALING_PATHWAY	2.0	0.007
	GAVISH_3CA_METAPROGRAM_CD8_T_CELLS_CHROMATIN	1.78	0.068
Endothelium dysfunction	GOBP_NEGATIVE_REGULATION_OF_ENDOTHELIAL_CELL_PROLIFERATION	-1.98	0.0017
	GOBP_NEGATIVE_REGULATION_OF_COAGULATION	-1.98	0.0017
Proliferative signaling and suppressed tumor control	REACTOME_ASSEMBLY_OF_THE_ORC_COMPLEX_AT_THE_ORIGIN_OF_REPLICATION	2.93	> 0.001
Genomic instability and epigenetic shift	REACTOME_DNA_METHYLATION	3.18	> 0.001
	REACTOME_CONDENSATION_OF_PROPHASE_CHROMOSOMES	2.93	> 0.001
	KEGG_MEDICUS_REFERENCE_CGAS_STING_SIGNALING_PATHWAY	2.43	> 0.001
	GAVISH_3CA_MALIGNANT_METAPROGRAM_4_CHROMATIN	1.91	0.05
	GOBP_NUCLEOSOME_ORGANIZATION	2.33	0.01

The Table 3 displays the top gene sets within each category, along with their corresponding MSigDB identifiers, Normalized Enrichment Score (NES), and false discovery rate (FDR) q value. Positive NES values indicate upregulation, while negative NES values indicate downregulation of the gene sets in vaccinated samples relative to controls. Gene sets were selected based on biological relevance and NES > |15| with FDR $q < 0.25$. Group 2 includes patients with new-onset cancers diagnosed shortly after messenger RNA coronavirus disease 2019 vaccination ($n = 7$), compared with normal controls ($n = 803$ unvaccinated individuals from the GTEx dataset).

be uncoupled; a long-lived, stable mRNA may be poorly translated if initiation is blocked, while rapid synthesis can deplete short-lived mRNAs. Ultimately, the overall protein output is a product of both the mRNA's availability and the efficiency of the translational machinery[45-47]. Enrichment of gene sets related to translation initiation, ribosome biogenesis, and mRNA surveillance suggests sustained activation of the protein synthesis machinery. In group 1, upregulated pathways such as translation initiation, cytoplasmic translation, and ribosomal subunit biogenesis indicate persistent engagement of ribosomes and translational apparatus, likely driven by prolonged spike protein expression from stabilized synthetic mRNA[8,16,18]. Enrichment of nonsense-mediated decay (NMD) related genes in patients with new-onset vaccine-associated adverse events contrasts with previous findings that SARS-CoV-2 virus suppresses NMD to protect its RNA genome[48,49]. This suggests that, unlike the viral genome, synthetic mRNA used in vaccination may instead provoke a compensatory activation of RNA surveillance mechanisms, potentially due to persistent translation or accumulation of aberrant transcripts. The opposing patterns of NMD regulation in these two contexts point to distinct cellular responses and warrant further investigation. In group 2, as in the first group, we observed significant enrichment



Figure 2 Protein-protein interaction network of the most dysregulated genes in group 1. A: Genes related to proliferative signaling and tumor control; B: Genes related to systemic inflammatory immune; C: Genes related to transcriptomic instability; D: Genes related to mitochondrial electron transport

dysfunction and reactive oxygen species; E: Genes related to proteasome-mediated protein degradation stress. Group 1 includes patients with new-onset adverse events following messenger RNA coronavirus disease 2019 vaccination (n = 3), compared with normal controls (n = 803 unvaccinated individuals from the GTEx dataset). Node color intensity reflects the degree of interaction (connectivity), with darker nodes indicating higher connectivity or a hub status within the network.

in gene sets related to ribosome biogenesis, cytoplasmic translation, and mRNA surveillance. However, the cancer group displayed more pronounced activation of ribosomal stress pathways, particularly those linked to RNA Polymerase I promoter escape, rRNA maturation, and positive epigenetic regulation of rRNA expression, indicating hyperactivation of nucleolar functions and elevated translational throughput. While these transcriptional programs are classically associated with tumor cells to support uncontrolled proliferation[50-52], their detection in peripheral blood samples likely reflects systemic consequences of underlying malignancy, such as systemic immune alterations or stress responses induced by tumor-related inflammation and signaling[53-55]. While the vaccine-adverse event group showed activation of NMD pathways, the cancer group displayed additional signals related to small RNA–mediated transcriptional regulation and epigenetic repression of ribosomal gene activity. The coexistence of transcriptional silencing and increased rRNA production may reflect underlying transcriptional stress affecting cellular balance.

Enrichments related to the hallmark of systemic inflammatory and immune response were identified in both groups analyzed in this work. In group 1, the most highly connected upregulated genes in the PPI network included *LOX*, *CD28*, *CCR7*, and *SELL*. Recent findings demonstrate that the use of m1Ψ in mRNA constructs can induce +1 ribosomal frameshifting, resulting in the production of off-target proteins that may elicit unintended cellular immune responses[9]. This aberrant antigen production may represent a novel mechanism contributing to systemic inflammation and immune dysregulation. In addition, emerging evidence suggests that cytoplasmic fragmentation of vaccine-derived mRNA may generate short RNA sequences with miRNA-like properties capable of hybridizing host immune transcripts, such as interferons and anti-inflammatory regulators. This unintended post-transcriptional interference could contribute to systemic immune dysregulation and inflammatory responses, particularly in individuals with predisposing comorbidities or impaired RNA degradation pathways[56]. In addition, numerous studies have previously demonstrated the inflammatory activity of mRNA LNPs[57-59]. Compared to group 1, where immune imbalance was more skewed toward aberrant cellular activation and humoral suppression, group 2 displayed a distinct pattern of innate immune activation. GSEA revealed the upregulation of pathways involving type I interferons, toll-like receptors, and nuclear factor kappa B (NF-κB)-driven inflammatory signaling. Enrichment of the RIG-I/MDA5–IRF7 axis, TLR3/7/8/9–IRF5/7, and the JAK-STAT interferon cascade suggests persistent engagement of RNA-sensing mechanisms and their downstream proinflammatory transcriptional programs. While these responses are central to antiviral immunity, their chronic activation in the peripheral blood of cancer patients might be related to inflammation, immune exhaustion, and tumor immune editing[60-62]. These immune alterations are consistent with previous findings in both elderly vaccine recipients and autoimmune patients, where IFN-JAK-STAT overactivation and RIG-I signaling were repeatedly identified as dominant signatures, underscoring that our observed systemic inflammation reflects a reproducible pattern across vaccinated cohorts[63].

For group 1, a negative NES for the angiogenesis hallmark suggests transcriptional downregulation or post-transcriptional inhibition of key angiogenic mediators. This may be linked to the RNA fragmentation hypothesis supported by Demongeot and Fougère's work[56], wherein miRNA-like fragments derived from cleaved vaccine mRNA hybridize with endothelial transcripts, suppressing their translation and contributing to systemic endothelial dysfunction and impaired vascular repair. In the cancer group, transcriptomic analysis revealed significant downregulation of gene sets involved in negative regulation of endothelial cell proliferation and negative regulation of coagulation. The suppression of these regulatory pathways may indicate uncontrolled endothelial activation or a vascular pro-thrombotic shift, conditions that can be linked to spike protein adverse events and tumor progression[64-67]. Proteome-mediated protein degradation stress, marked by impaired ubiquitin-proteasome and autophagy pathways, contributes to the accumulation of misfolded or damaged proteins that sustain inflammation and cellular dysfunction. This ongoing proteotoxic stress is thought to contribute to the chronic fatigue, neurological dysfunction, and multi-organ symptoms in vaccinated patients[68,69].

For both groups 1 and 2, we could note an enrichment in the Proliferative Signaling and Suppressed Tumor Control Hallmark genes signatures. For group 1, positive enrichment in gene sets regulated by myelocytomatosis oncogene (MYC) suggests an active oncogenic transcriptional program that favors tumor growth and adaptation. This proliferative bias is compounded by the downregulation of tumor-suppressive pathways, including the KRAS-inhibited signature, p53 regulatory networks, and inhibitors of the Wnt pathway. Figure 2A depicts the PPI network for these hallmarks in group 1, highlighting the key interconnected genes driving these processes. These findings suggest a microenvironment conducive to unchecked cellular expansion, loss of apoptotic surveillance, and diminished responsiveness to anti-proliferative signals. Notably, many previous studies have reported that the spike protein can trigger the mitogen pathway, through the downregulation of angiotensin-converting enzyme 2 (ACE2) expression, which promotes an angiotensin II type I receptor (AT1R)-mediated signaling cascade, inducing the transcriptional regulatory molecules NF-κB and activator protein 1/c-Fos *via* mitogen-activated protein kinase activation[70-72]. In accordance with this molecular pathway, our investigated patients from group 1 and group 2 also presented a very downregulated ACE2 expression compared to normal control (logfold change: -4.3 and -4.8, respectively). In relation to this hallmark, group 2 showed enrichment of pathways involved in the DNA replication process, specifically the Assembly of the ORC Complex at the Origin of Replication, reflecting heightened replicative stress and uncontrolled proliferation potentially driven by tumor-related systemic effects or prolonged immune activation[60-62].

Only group 2 presented enrichments related to the Genomic Instability and Epigenetic Shift hallmark. Key pathways enriched show aberrant regulation of histone modification, DNA packaging, and epigenetic silencing, which are commonly observed in oncogenic events. In parallel, enrichment of the cGAS–STING signaling pathway points to innate



Figure 3 Protein-protein interaction network of the most dysregulated genes in group 2. A: Genes related to transcriptomic instability, translational stress; B: Genes related to genomic instability and epigenetic shift; C: Genes associated with endothelial dysfunction; D: Genes related to systemic inflammatory and immune response; E: Genes that are related to proliferative signaling and suppressed tumor control. Group 2 includes patients with new-onset cancers diagnosed shortly after messenger RNA coronavirus disease 2019 vaccination (*n* = 7), compared with normal controls (*n* = 803 unvaccinated individuals from the GTEx dataset). Node color intensity reflects the degree of interaction (connectivity), with darker nodes indicating higher connectivity or a hub status within the network.



Figure 4 Transcriptomic alterations following messenger RNA vaccination. This central illustration summarizes the experimental design, core findings, and proposed molecular mechanisms underlying transcriptomic dysregulation following synthetic messenger RNA (mRNA) coronavirus disease 2019 vaccination. Top left: Schematic of mRNA vaccination, showing lipid nanoparticle-encapsulated, chemically modified mRNA encoding spike protein delivered into host cells, initiating persistent translation and immunologic engagement. Top right: Volcano plots depict global differential gene expression in peripheral blood samples from two affected cohorts *vs* normal controls (n = 803). Left: Individuals with new-onset nonmalignant adverse events (n = 3). Right: Individuals with new-onset cancer (n = 7). Upregulated genes [$\log_2$FC > 1, adjusted P value (P_{adj}) < 0.05] are shown in red; downregulated genes ($\log_2$FC < -1, P_{adj} < 0.05) in blue; non-significant genes in gray. Bottom left (new-onset adverse events): Transcriptomic analysis reveals enrichment of pathways linked to mitochondrial electron transport dysfunction and reactive oxygen species, proteasome-mediated protein degradation stress, mRNA surveillance activation, and systemic inflammatory signaling. Bottom right (new-onset cancer): Cancer patients exhibit hallmarks of oncogenesis, including genomic instability, epigenetic reprogramming, nonsense-mediated decay, ribosomal stress, myelocytomatosis oncogene-driven proliferative signaling, and persistent immune activation *via* toll-like receptors and type I interferons. COVID-19: Coronavirus disease 2019; mRNA: Messenger RNA; MYC: Myelocytomatosis oncogene; ROS: Reactive oxygen species; TCA: Tricarboxylic acid; TLRs: Toll-like receptors;

immune recognition of cytoplasmic DNA fragments, a well-established marker of DNA damage and chromosomal instability[73]. This pathway is associated with tumor-promoting inflammation and immune editing[60-62]. Importantly, a recent longitudinal study of mRNA vaccination in octogenarians demonstrated that BNT162b2 administration elicited activation of the cGAS–STING pathway alongside robust immune and antibody responses, further supporting our transcriptomic findings[63]. Persistent genomic instability increases the likelihood of acquiring somatic mutations in key oncogenes and tumor suppressor genes, a process that can cumulatively drive malignant transformation. This is consistent with preclinical and *in vitro* evidence showing that exposure to the BNT162b2 mRNA vaccine can modulate endogenous reverse transcriptase activity (LINE-1), facilitate reverse transcription of vaccine mRNA into DNA, and alter nuclear localization of LINE-1 proteins[74], such events that could, in principle, contribute to insertional mutagenesis and genomic perturbations over time. Independent analyses have corroborated these concerns by identifying residual plasmid DNA contamination in both Pfizer and Moderna mRNA vaccines[75].

CONCLUSION

This study provides transcriptomic evidence of molecular disruptions in two patient populations – those with new-onset nonmalignant adverse events and those with newly diagnosed cancers. Using differential expression analysis and GSEA, we identified hallmark signatures of mitochondrial dysfunction, translational stress, immune dysregulation, endothelial disturbance, and proliferative signaling across both cohorts. Notably, while both groups shared transcriptional perturbations in immune and translational pathways, the cancer group exhibited additional signatures of genomic instability and

epigenetic remodeling.

Persistent spike protein expression, prolonged synthetic mRNA activity, and RNA modifications such as m1Ψ appear to contribute to sustained aberrant ribosomal activity, proteostasis stress, and immune activation. Our findings also highlight transcriptional signals indicative of tumor-promoting conditions, including suppressed p53 networks, activated MYC targets, and altered interferon signaling, particularly in the context of epigenetic dysregulation in the cancer cohort. These observations suggest that vaccine-induced transcriptomic reprogramming may differentially affect individuals, genetically or immunologically, over a long period of time after vaccination. Despite the smaller sample size due to resource constraints (group 1 $n = 3$ *vs* $n = 7$ in group 2), the findings open an important avenue for understanding post-vaccine biological responses and underscore the value of expanding future studies with larger cohorts.

ACKNOWLEDGEMENTS

We thank the Genomics Center at the University of North Texas for sequencing support, Neo7Bioscience for data interpretation assistance, and the McCullough Foundation for scientific collaboration. We also acknowledge the participants who made this study possible.

FOOTNOTES

Author contributions: Von Ranke NL and Zhang W led the interpretation of results; Anokhin P prepared the datasets for analysis; Hulscher N, McKernan K, and Mccullough P provided scientific support and research oversight; Catanzaro J served as the principal investigator for this study and supervised and conceived the research; all authors reviewed and approved the final manuscript.

Institutional review board statement: The study was reviewed and approved by the Neo7Bioscience SpikeX Institutional Review Board (No. IRB00014606), which is registered with the United States, Department of Health and Human Services. Approval was granted under protocol number Neo7-RB-2024-001 on January 15, 2025.

Informed consent statement: All study participants were informed that the participation is voluntary, involves providing a blood sample for transcriptomic analysis, de-identified data may be used in scientific research and publications. Informed consent was obtained from all subjects involved in the study, and all data were de-identified before analysis.

Conflict-of-interest statement: This study was funded by Neo7Bioscience, which was involved in the study design, data collection, analysis, and manuscript preparation. Natalia Lidmar Von Ranke, Wei Zhang, and Philipp Anokhin, who processed and analyzed the data, receive salary support from Neo7Bioscience. John Catanzaro, who conceived the study and served as Principal Investigator, is the CEO and a shareholder of Neo7Bioscience and also receives salary support from the company. Neo7Bioscience is a privately held biotechnology company specializing in the development of personalized therapeutic peptides. Nicolas Hulscher, who provided scientific input, receives salary support from the McCullough Foundation. Peter McCullough, who provided research oversight, is the founder of the McCullough Foundation but receives no compensation from the organization. The McCullough Foundation is a nonprofit entity dedicated to advancing independent public health research, medical ethics, and evidence-based policy. Kevin McKernan, who also provided scientific support, is the founder, Chief Scientific Officer, and a shareholder of Medicinal Genomics, a company that provides genomic services to the agricultural sector.

Data sharing statement: Deidentified transcriptomic data was deposited in secure, open-access repositories to advance scientific knowledge, in accordance with institutional and ethical guidelines. The datasets generated and analyzed during the current study are publicly available in the NCBI Gene Expression Omnibus (GEO) under accession code GSE304973 (GEO Accession viewer). Control RNA-seq data used for comparison were obtained from the GTEx dataset (GTEx Portal).

STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.

Country of origin: United States

ORCID number: Natalia Lidmar Von Ranke 0000-0003-0045-9252; Wei Zhang 0009-0005-2954-0179; Nicolas Hulscher 0009-0008-0677-7386; Kevin McKernan 0000-0002-3908-1122; Peter Mccullough 0000-0002-0997-6355; John Catanzaro 0000-0002-0710-2929.

S-Editor: Luo ML
L-Editor: A
P-Editor: Zhao S

REFERENCES

1 **Acevedo-Whitehouse K**, Bruno R. Potential health risks of mRNA-based vaccine therapy: A hypothesis. *Med Hypotheses* 2023; **171**: 111015 [*RCA*] [PMID: 36718314 DOI: 10.1016/j.mehy.2023.111015] [FullText] [Full Text(PDF)]

2 **Li YE**, Wang S, Reiter RJ, Ren J. Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality? *Int J Infect Dis* 2022; **124**: 1-10 [*RCA*] [PMID: 36075372 DOI: 10.1016/j.ijid.2022.08.026] [FullText] [Full Text(PDF)]

3 **Mohseni Afshar Z**, Tavakoli Pirzaman A, Liang JJ, Sharma A, Pirzadeh M, Babazadeh A, Hashemi E, Deravi N, Abdi S, Allahgholipour A, Hosseinzadeh R, Vaziri Z, Sio TT, Sullman MJM, Barary M, Ebrahimpour S. Do we miss rare adverse events induced by COVID-19 vaccination? *Front Med (Lausanne)* 2022; **9**: 933914 [*RCA*] [PMID: 36300183 DOI: 10.3389/fmed.2022.933914] [FullText]

4 **Yasmin F**, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, Nimri N, Saleem M, Bandyopadhyay D, Krittanawong C, Fadelallah Eljack MM, Tahir MJ, Waqar F. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. *Immun Inflamm Dis* 2023; **11**: e807 [*RCA*] [PMID: 36988252 DOI: 10.1002/iid3.807] [FullText] [Full Text (PDF)]

5 **Yoon D**, Jeon HL, Noh Y, Choe YJ, Choe SA, Jung J, Shin JY. A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors. *J Korean Med Sci* 2023; **38**: e170 [*RCA*] [PMID: 37272559 DOI: 10.3346/jkms.2023.38.e170] [FullText]

6 **Nyström S**, Hammarström P. Amyloidogenesis of SARS-CoV-2 Spike Protein. *J Am Chem Soc* 2022; **144**: 8945-8950 [*RCA*] [PMID: 35579205 DOI: 10.1021/jacs.2c03925] [FullText] [Full Text(PDF)]

7 **Manniche V**, Fürst T, Schmeling M, Gilthorpe JD, Hansen PR. Rates of successful conceptions according to COVID-19 vaccination status: Data from the Czech Republic. *Int J Risk Saf Med* 2025; 9246479251353384 [*RCA*] [PMID: 40534497 DOI: 10.1177/09246479251353384] [FullText] [Full Text(PDF)]

8 **Seneff S**, Kyriakopoulos AM, Nigh G, McCullough PA. A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review. *Cureus* 2023; **15**: e34872 [*RCA*] [PMID: 36788995 DOI: 10.7759/cureus.34872] [FullText]

9 **Stiving AQ**, Roose BW, Tubbs C, Haverick M, Gruber A, Rustandi RR, Kuiper J, Schombs M, Schuessler H, Li X. Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection. *NPJ Vaccines* 2025; **10**: 38 [*RCA*] [PMID: 39988579 DOI: 10.1038/s41541-025-01082-4] [FullText]

10 **Lim S**, Yocum RR, Silver PA, Way JC. High spontaneous integration rates of end-modified linear DNAs upon mammalian cell transfection. *Sci Rep* 2023; **13**: 6835 [*RCA*] [PMID: 37100816 DOI: 10.1038/s41598-023-33862-0] [FullText]

11 **Šenigl F**, Soikkeli AI, Prost S, Schatz DG, Slavková M, Hejnar J, Alinikula J. The SV40 virus enhancer functions as a somatic hypermutation-targeting element with potential tumorigenic activity. *Tumour Virus Res* 2024; **18**: 200293 [*RCA*] [PMID: 39490533 DOI: 10.1016/j.tvr.2024.200293] [FullText] [Full Text(PDF)]

12 **Dean DA**, Dean BS, Muller S, Smith LC. Sequence requirements for plasmid nuclear import. *Exp Cell Res* 1999; **253**: 713-722 [*RCA*] [PMID: 10585295 DOI: 10.1006/excr.1999.4716] [FullText]

13 **Kämmerer U**, Schulz V, Steger K. BioNTech RNA-Based COVID-19 Injections Contain Large Amounts of Residual DNA Including an SV40 Promoter/Enhancer Sequence. *Sci Public Health Policy Law* 2024; **v5.2019-2024**

14 **Drayman N**, Ben-Nun-Shaul O, Butin-Israeli V, Srivastava R, Rubinstein AM, Mock CS, Elyada E, Ben-Neriah Y, Lahav G, Oppenheim A. p53 elevation in human cells halt SV40 infection by inhibiting T-ag expression. *Oncotarget* 2016; **7**: 52643-52660 [*RCA*] [PMID: 27462916 DOI: 10.18632/oncotarget.10769] [FullText] [Full Text(PDF)]

15 **Strayer D**, Branco F, Zern MA, Yam P, Calarota SA, Nichols CN, Zaia JA, Rossi J, Li H, Parashar B, Ghosh S, Chowdhury JR. Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. *Mol Ther* 2002; **6**: 227-237 [*RCA*] [PMID: 12161189 DOI: 10.1006/mthe.2002.0657] [FullText]

16 **Patterson BK**, Yogendra R, Francisco EB, Guevara-Coto J, Long E, Pise A, Osgood E, Bream J, Kreimer M, Jeffers D, Beaty C, Vander Heide R, Mora-Rodríguez RA. Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals. *Hum Vaccin Immunother* 2025; **21**: 2494934 [*RCA*] [PMID: 40358138 DOI: 10.1080/21645515.2025.2494934] [FullText] [Full Text(PDF)]

17 **Boros LG**, Kyriakopoulos AM, Brogna C, Piscopo M, McCullough PA, Seneff S. Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination. *Pharmacol Res Perspect* 2024; **12**: e1218 [*RCA*] [PMID: 38867495 DOI: 10.1002/prp2.1218] [FullText]

18 **Yonker LM**, Swank Z, Bartsch YC, Burns MD, Kane A, Boribong BP, Davis JP, Loiselle M, Novak T, Senussi Y, Cheng CA, Burgess E, Edlow AG, Chou J, Dionne A, Balaguru D, Lahoud-Rahme M, Arditi M, Julg B, Randolph AG, Alter G, Fasano A, Walt DR. Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis. *Circulation* 2023; **147**: 867-876 [*RCA*] [PMID: 36597886 DOI: 10.1161/CIRCULATIONAHA.122.061025] [FullText]

19 **Karikari AA**, McFleder RL, Ribechini E, Blum R, Bruttel V, Knorr S, Gehmeyr M, Volkmann J, Brotchie JM, Ahsan F, Haack B, Monoranu CM, Keber U, Yeghiazaryan R, Pagenstecher A, Heckel T, Bischler T, Wischhusen J, Koprich JB, Lutz MB, Ip CW. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice. *Brain Behav Immun* 2022; **101**: 194-210 [*RCA*] [PMID: 35032575 DOI: 10.1016/j.bbi.2022.01.007] [FullText]

20 **GTEx Consortium**. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013; **45**: 580-585 [*RCA*] [PMID: 23715323 DOI: 10.1038/ng.2653] [FullText]

21 **Anders S**, Huber W. Differential expression analysis for sequence count data. *Genome Biol* 2010; **11**: R106 [*RCA*] [PMID: 20979621 DOI: 10.1186/gb-2010-11-10-r106] [FullText] [Full Text(PDF)]

22 **Dobin A**, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013; **29**: 15-21 [*RCA*] [PMID: 23104886 DOI: 10.1093/bioinformatics/bts635] [FullText]

23 **Patro R**, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods* 2017; **14**: 417-419 [*RCA*] [PMID: 28263959 DOI: 10.1038/nmeth.4197] [FullText] [Full Text(PDF)]

24 **Love MI**, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014; **15**: 550 [*RCA*] [PMID: 25516281 DOI: 10.1186/s13059-014-0550-8] [FullText] [Full Text(PDF)]

25 **Subramanian A**, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;

102: 15545-15550 [*RCA*] [PMID: 16199517 DOI: 10.1073/pnas.0506580102] [FullText]

26 **Liberzon A**, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* 2015; **1**: 417-425 [*RCA*] [PMID: 26771021 DOI: 10.1016/j.cels.2015.12.004] [FullText]

27 **Szklarczyk D**, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res* 2015; **43**: D447-D452 [*RCA*] [PMID: 25352553 DOI: 10.1093/nar/gku1003] [FullText] [Full Text(PDF)]

28 **Rao VS**, Srinivas K, Sujini GN, Kumar GN. Protein-protein interaction detection: methods and analysis. *Int J Proteomics* 2014; **2014**: 147648 [*RCA*] [PMID: 24693427 DOI: 10.1155/2014/147648] [FullText] [Full Text(PDF)]

29 **Bebek G**. Identifying gene interaction networks. *Methods Mol Biol* 2012; **850**: 483-494 [*RCA*] [PMID: 22307715 DOI: 10.1007/978-1-61779-555-8_26] [FullText]

30 **Hanes R**, Zhang F, Huang Z. Protein Interaction Network Analysis to Investigate Stress Response, Virulence, and Antibiotic Resistance Mechanisms in Listeria monocytogenes. *Microorganisms* 2023; **11**: 930 [*RCA*] [PMID: 37110353 DOI: 10.3390/microorganisms11040930] [FullText] [Full Text(PDF)]

31 **Szklarczyk D**, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, Bork P, Jensen LJ, von Mering C. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids Res* 2023; **51**: D638-D646 [*RCA*] [PMID: 36370105 DOI: 10.1093/nar/gkac1000] [FullText] [Full Text (PDF)]

32 **Speicher DJ**, Rose J, Gutschi LM, Wiseman DM, Mckernan K. DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. 2023 Preprint. Available from: OSF [DOI: 10.31219/osf.io/mjc97] [FullText]

33 **Trougakos IP**, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, Kastritis E, Andreakos E, Dimopoulos MA. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. *Trends Mol Med* 2022; **28**: 542-554 [*RCA*] [PMID: 35537987 DOI: 10.1016/j.molmed.2022.04.007] [FullText] [Full Text(PDF)]

34 **Fang L**, Tang T, Hu M. Identification of Differentially Expressed Genes in COVID-19 and Integrated Bioinformatics Analysis of Signaling Pathways. *Genet Res (Camb)* 2021; **2021**: 2728757 [*RCA*] [PMID: 35002537 DOI: 10.1155/2021/2728757] [FullText] [Full Text(PDF)]

35 **Chang X**, Ismail NI, Rahman A, Xu D, Chan RWY, Ong SG, Ong SB. Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link? *Antioxid Redox Signal* 2023; **38**: 599-618 [*RCA*] [PMID: 36053670 DOI: 10.1089/ars.2022.0126] [FullText]

36 **Molnar T**, Lehoczki A, Fekete M, Varnai R, Zavori L, Erdo-Bonyar S, Simon D, Berki T, Csecsei P, Ezer E. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. *Geroscience* 2024; **46**: 5267-5286 [*RCA*] [PMID: 38668888 DOI: 10.1007/s11357-024-01165-5] [FullText] [Full Text(PDF)]

37 **Rurek M**. Mitochondria in COVID-19: from cellular and molecular perspective. *Front Physiol* 2024; **15**: 1406635 [*RCA*] [PMID: 38974521 DOI: 10.3389/fphys.2024.1406635] [FullText]

38 **Cao X**, Nguyen V, Tsai J, Gao C, Tian Y, Zhang Y, Carver W, Kiaris H, Cui T, Tan W. The SARS-CoV-2 spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice. *Mol Metab* 2023; **74**: 101756 [*RCA*] [PMID: 37348737 DOI: 10.1016/j.molmet.2023.101756] [FullText] [Full Text(PDF)]

39 **Gonzalez VJ**, Li L, Buarpung S, Prahl M, Robinson JF, Gaw SL. Minimal mRNA uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human placental explants. *iScience* 2023; **26**: 107549 [*RCA*] [PMID: 37664582 DOI: 10.1016/j.isci.2023.107549] [Full Text] [Full Text(PDF)]

40 **Castruita JAS**, Schneider UV, Mollerup S, Leineweber TD, Weis N, Bukh J, Pedersen MS, Westh H. SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination. *APMIS* 2023; **131**: 128-132 [*RCA*] [PMID: 36647776 DOI: 10.1111/apm.13294] [FullText] [Full Text(PDF)]

41 **Krauson AJ**, Casimero FVC, Siddiquee Z, Stone JR. Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. *NPJ Vaccines* 2023; **8**: 141 [*RCA*] [PMID: 37758751 DOI: 10.1038/s41541-023-00742-7] [Full Text]

42 **Röltgen K**, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, Yang F, Wirz OF, Solis D, Hoh RA, Wang A, Arunachalam PS, Colburg D, Zhao S, Haraguchi E, Lee AS, Shah MM, Manohar M, Chang I, Gao F, Mallajosyula V, Li C, Liu J, Shoura MJ, Sindher SB, Parsons E, Dashdorj NJ, Dashdorj ND, Monroe R, Serrano GE, Beach TG, Chinthrajah RS, Charville GW, Wilbur JL, Wohlstadter JN, Davis MM, Pulendran B, Troxell ML, Sigal GB, Natkunam Y, Pinsky BA, Nadeau KC, Boyd SD. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. *Cell* 2022; **185**: 1025-1040.e14 [*RCA*] [PMID: 35148837 DOI: 10.1016/j.cell.2022.01.018] [FullText] [Full Text(PDF)]

43 **Ota N**, Itani M, Aoki T, Sakurai A, Fujisawa T, Okada Y, Noda K, Arakawa Y, Tokuda S, Tanikawa R. Expression of SARS-CoV-2 spike protein in cerebral Arteries: Implications for hemorrhagic stroke Post-mRNA vaccination. *J Clin Neurosci* 2025; **136**: 111223 [*RCA*] [PMID: 40184822 DOI: 10.1016/j.jocn.2025.111223] [FullText]

44 **Mueed A**, Shariq A, Ashar M. Critical appraisal of: "expression of SARS-CoV-2 spike protein in cerebral arteries: implications for hemorrhagic stroke post-mRNA vaccination". *J Clin Neurosci* 2025; **136**: 111270 [*RCA*] [PMID: 40267596 DOI: 10.1016/j.jocn.2025.111270] [FullText]

45 **Holcik M**, Sonenberg N. Translational control in stress and apoptosis. *Nat Rev Mol Cell Biol* 2005; **6**: 318-327 [*RCA*] [PMID: 15803138 DOI: 10.1038/nrm1618] [FullText]

46 **Darnell JC**, Richter JD. Cytoplasmic RNA-binding proteins and the control of complex brain function. *Cold Spring Harb Perspect Biol* 2012; **4**: a012344 [*RCA*] [PMID: 22723494 DOI: 10.1101/cshperspect.a012344] [FullText]

47 **Sonenberg N**, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. *Cell* 2009; **136**: 731-745 [*RCA*] [PMID: 19239892 DOI: 10.1016/j.cell.2009.01.042] [FullText] [Full Text(PDF)]

48 **Mallick M**, Boehm V, Xue G, Blackstone M, Gehring NH, Chakrabarti S. Modulation of UPF1 catalytic activity upon interaction of SARS-CoV-2 Nucleocapsid protein with factors involved in nonsense mediated-mRNA decay. *Nucleic Acids Res* 2024; **52**: 13325-13339 [*RCA*] [PMID: 39360627 DOI: 10.1093/nar/gkae829] [FullText]

49 **Nuccetelli V**, Mghezzi-Habellah M, Deymier S, Roisin A, Gérard-Baraggia F, Rocchi C, Coureux PD, Gouet P, Cimarelli A, Mocquet V, Fiorini F. The SARS-CoV-2 nucleocapsid protein interferes with the full enzymatic activation of UPF1 and its interaction with UPF2. *Nucleic Acids Res* 2025; **53**: gkaf010 [*RCA*] [PMID: 39831305 DOI: 10.1093/nar/gkaf010] [FullText]

50 **Pitts S**, Laiho M. Regulation of RNA Polymerase I Stability and Function. *Cancers (Basel)* 2022; **14**: 5776 [*RCA*] [PMID: 36497261 DOI: 10.3390/cancers14235776] [FullText]

51 **Ferreira R**, Schneekloth JS Jr, Panov KI, Hannan KM, Hannan RD. Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age. *Cells* 2020; **9**: 266 [*RCA*] [PMID: 31973211 DOI: 10.3390/cells9020266] [FullText] [Full Text(PDF)]

52 **López J**, Blanco S. Exploring the role of ribosomal RNA modifications in cancer. *Curr Opin Genet Dev* 2024; **86**: 102204 [*RCA*] [PMID: 38759459 DOI: 10.1016/j.gde.2024.102204] [FullText]

53 **Abusanad A**. Utilizing peripheral blood inflammatory biomarker (PBIB) to predict response to systemic therapy in patients with breast cancer. *J Family Med Prim Care* 2023; **12**: 3368-3373 [*RCA*] [PMID: 38361878 DOI: 10.4103/jfmpc.jfmpc_1125_23] [FullText] [Full Text(PDF)]

54 **Huai Q**, Luo C, Song P, Bie F, Bai G, Li Y, Liu Y, Chen X, Zhou B, Sun X, Guo W, Gao S. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy. *Cancer Sci* 2023; **114**: 4484-4498 [*RCA*] [PMID: 37731264 DOI: 10.1111/cas.15964] [FullText] [Full Text(PDF)]

55 **Xie Y**, Yu Q, Zhu Y, Wu W, Xiao R, Wang N, Zhu L, Li P, Chen T. The value of peripheral blood inflammation markers in risk assessment and prediction of lung cancer. *Future Sci OA* 2025; **11**: 2476870 [*RCA*] [PMID: 40079245 DOI: 10.1080/20565623.2025.2476870] [FullText]

56 **Demongeot J**, Fougère C. mRNA COVID-19 Vaccines-Facts and Hypotheses on Fragmentation and Encapsulation. *Vaccines (Basel)* 2022; **11**: 40 [*RCA*] [PMID: 36679885 DOI: 10.3390/vaccines11010040] [FullText]

57 **Kiaie SH**, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, Jafari R. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. *J Nanobiotechnology* 2022; **20**: 276 [*RCA*] [PMID: 35701851 DOI: 10.1186/s12951-022-01478-7] [FullText] [Full Text(PDF)]

58 **Parry PI**, Lefringhausen A, Turni C, Neil CJ, Cosford R, Hudson NJ, Gillespie J. 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA. *Biomedicines* 2023; **11**: 2287 [*RCA*] [PMID: 37626783 DOI: 10.3390/biomedicines11082287] [FullText] [Full Text(PDF)]

59 **Sharma P**, Hoorn D, Aitha A, Breier D, Peer D. The immunostimulatory nature of mRNA lipid nanoparticles. *Adv Drug Deliv Rev* 2024; **205**: 115175 [*RCA*] [PMID: 38218350 DOI: 10.1016/j.addr.2023.115175] [FullText]

60 **Hu A**, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. *Signal Transduct Target Ther* 2024; **9**: 68 [*RCA*] [PMID: 38523155 DOI: 10.1038/s41392-024-01765-9] [FullText] [Full Text(PDF)]

61 **Maiorino L**, Daßler-Plenker J, Sun L, Egeblad M. Innate Immunity and Cancer Pathophysiology. *Annu Rev Pathol* 2022; **17**: 425-457 [*RCA*] [PMID: 34788549 DOI: 10.1146/annurev-pathmechdis-032221-115501] [FullText]

62 **Yi M**, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z, Wu K. Exploiting innate immunity for cancer immunotherapy. *Mol Cancer* 2023; **22**: 187 [*RCA*] [PMID: 38008741 DOI: 10.1186/s12943-023-01885-w] [FullText] [Full Text(PDF)]

63 **Lee HK**, Knabl L, Moliva JI, Knabl L Sr, Werner AP, Boyoglu-Barnum S, Kapferer S, Pateter B, Walter M, Sullivan NJ, Furth PA, Hennighausen L. mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron. *Cell Rep* 2022; **39**: 110680 [*RCA*] [PMID: 35395191 DOI: 10.1016/j.celrep.2022.110680] [FullText] [Full Text(PDF)]

64 **Blann AD**. Endothelial cell activation markers in cancer. *Thromb Res* 2012; **129** Suppl 1: S122-S126 [*RCA*] [PMID: 22682122 DOI: 10.1016/S0049-3848(12)70031-2] [FullText]

65 **Smeda M**, Przyborowski K, Stojak M, Chlopicki S. The endothelial barrier and cancer metastasis: Does the protective facet of platelet function matter? *Biochem Pharmacol* 2020; **176**: 113886 [*RCA*] [PMID: 32113813 DOI: 10.1016/j.bcp.2020.113886] [FullText]

66 **Zheng Y**, Zhao J, Li J, Guo Z, Sheng J, Ye X, Jin G, Wang C, Chai W, Yan J, Liu D, Liang X. SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate. *Int J Biol Macromol* 2021; **193**: 1124-1129 [*RCA*] [PMID: 34743814 DOI: 10.1016/j.ijbiomac.2021.10.112] [FullText] [Full Text(PDF)]

67 **Becker RC**, Tantry US, Khan M, Gurbel PA. The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management. *J Thromb Thrombolysis* 2025; **58**: 15-49 [*RCA*] [PMID: 39179952 DOI: 10.1007/s11239-024-03028-4] [FullText]

68 **Menezes F**, Palmeira JDF, Oliveira JDS, Argañaraz GA, Soares CRJ, Nóbrega OT, Ribeiro BM, Argañaraz ER. Unraveling the SARS-CoV-2 spike protein long-term effect on neuro-PASC. *Front Cell Neurosci* 2024; **18**: 1481963 [*RCA*] [PMID: 39744674 DOI: 10.3389/fncel.2024.1481963] [FullText] [Full Text(PDF)]

69 **Peppercorn K**, Edgar CD, Kleffmann T, Tate WP. A pilot study on the immune cell proteome of long COVID patients shows changes to physiological pathways similar to those in myalgic encephalomyelitis/chronic fatigue syndrome. *Sci Rep* 2023; **13**: 22068 [*RCA*] [PMID: 38086949 DOI: 10.1038/s41598-023-49402-9] [FullText]

70 **Valdes Angues R**, Perea Bustos Y. SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis. *Cureus* 2023; **15**: e50703 [*RCA*] [PMID: 38234925 DOI: 10.7759/cureus.50703] [FullText]

71 **Patra T**, Meyer K, Geerling L, Isbell TS, Hoft DF, Brien J, Pinto AK, Ray RB, Ray R. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells. *PLoS Pathog* 2020; **16**: e1009128 [*RCA*] [PMID: 33284859 DOI: 10.1371/journal.ppat.1009128] [FullText] [Full Text(PDF)]

72 **Suzuki YJ**, Gychka SG. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. *Vaccines (Basel)* 2021; **9**: 36 [*RCA*] [PMID: 33440640 DOI: 10.3390/vaccines9010036] [FullText] [Full Text(PDF)]

73 **Kwon J**, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. *Cancer Discov* 2020; **10**: 26-39 [*RCA*] [PMID: 31852718 DOI: 10.1158/2159-8290.CD-19-0761] [FullText]

74 **Aldén M**, Olofsson Falla F, Yang D, Barghouth M, Luan C, Rasmussen M, De Marinis Y. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. *Curr Issues Mol Biol* 2022; **44**: 1115-1126 [*RCA*] [PMID: 35723296 DOI: 10.3390/cimb44030073] [FullText] [Full Text(PDF)]

75 **Chakraborty S**. The bloodstream of mRNA vaccinated individuals (both Pfizer and Moderna) shows DNA expression vector contamination, including SV40 and kanamycin-resistant gene sequences. 2024 Preprint. Available from: OSF [DOI: 10.31219/osf.io/hzyn3] [FullText]

Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com